2360:TWSEBest Mart 360 Holdings Limited Analysis
Data as of 2026-03-14 - not real-time
NT$1,530.00
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Chroma ATE’s price is firmly above its short‑term and medium‑term moving averages, with the 20‑day SMA sitting on top of the 50‑day and 200‑day lines, confirming a bullish technical backdrop. The RSI sits in the high‑sixties, indicating strong momentum that is edging toward overbought territory, while the MACD histogram remains positive and volume is on an upward trend, suggesting continued buying pressure.
Fundamentally, the company posts robust top‑line growth and exceptionally high gross and operating margins, delivering a profit margin that outpaces many peers. However, valuation metrics tell a different story: the price‑to‑earnings multiple is well above the sector average and the discounted cash‑flow model points to a fair value far beneath the current market price, implying a material overvaluation. The dividend payout is modest with a low yield, yet cash flow generation and a manageable payout ratio support its sustainability.
Given the convergence of strong technical momentum, premium valuation, and solid fundamentals, investors should weigh the upside potential against the risk of a valuation correction. The stock’s proximity to its 52‑week high and technical resistance adds a near‑term caution flag, while the long‑term growth narrative remains compelling.
Fundamentally, the company posts robust top‑line growth and exceptionally high gross and operating margins, delivering a profit margin that outpaces many peers. However, valuation metrics tell a different story: the price‑to‑earnings multiple is well above the sector average and the discounted cash‑flow model points to a fair value far beneath the current market price, implying a material overvaluation. The dividend payout is modest with a low yield, yet cash flow generation and a manageable payout ratio support its sustainability.
Given the convergence of strong technical momentum, premium valuation, and solid fundamentals, investors should weigh the upside potential against the risk of a valuation correction. The stock’s proximity to its 52‑week high and technical resistance adds a near‑term caution flag, while the long‑term growth narrative remains compelling.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near technical resistance and 52‑week high
- RSI approaching overbought levels
- Positive MACD but valuation gap
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Sustained revenue growth and strong margins
- Robust operating cash flow supporting earnings expansion
- Analyst consensus of strong‑buy despite current overvaluation
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- High return on equity and continued cash generation
- Strategic positioning in high‑growth test‑equipment markets
- Dividend sustainability coupled with solid balance‑sheet strength
Key Metrics & Analysis
Financial Health
Revenue Growth42.10%
Profit Margin41.30%
P/E Ratio61.3
ROE41.12%
ROA13.61%
Debt/Equity11.94
P/B Ratio20.3
Op. Cash FlowNT$5.3B
Free Cash FlowNT$1.2B
Industry P/E33.7
Technical Analysis
TrendBullish
RSI68.3
SupportNT$928.00
ResistanceNT$1,570.00
MA 20NT$1,262.80
MA 50NT$1,057.94
MA 200NT$685.74
MACDBullish
VolumeIncreasing
Fear & Greed Index72.88
Valuation
Fair ValueNT$112.71
Target PriceNT$1,337.57
Upside/Downside-12.58%
GradeOvervalued
TypeGrowth
Dividend Yield0.59%
Risk Assessment
Beta0.94
Volatility84.13%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.